At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
Cannabidioldrug
Likely dose
Cannabidiol 2.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study
In Brief
A Phase 2 clinical trial evaluating Cannabidiol for Obsessive-Compulsive Disorder and 3 related conditions. Completed, enrolled 4 participants across 1 site.
Detailed Summary
The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome, Hoarding Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJul 2021
Enrollment StartApr 2022
Primary CompletionNov 2025
TodayJul 2026
First PostedJul 27, 2021
Enrollment StartApr 14, 2022
Primary CompletionNov 1, 2025
TodayJul 1, 2026
Enrollment to primary: 3.5 yearsPosted 4.9 years ago
Interventions
Cannabidioldrug
Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)